A B O R T I O N
Americans United for Life | Defending Life245
[Drafer’s Note: AUL has drafed detailed talking points to assist those interested in introducing this model in preparing or and countering arguments typically raised by abortion providers. Tose talking points are aailable upon request by contacting AUL’s Legislatie Coordinator at (202) 741-4907 or Legislation@AUL.org
Section 1. Title.
Tis Act may be known and cited as the “Abortion-Inducing Drugs Saety Act.”
Section 2. Legislative Findings and Purposes.
A. Te [
] o the State o [
Insert name o State
] fnds that:1. Te Food and Drug Administration (FDA) approved the drug miepristone (brand name“Mieprex”), a frst-generation [selective] progesterone receptor modulator ([S]PRM), as an abortion-inducing drug with a specifc gestation, dosage, and administration protocol.2. As approved by the FDA, and as outlined in the Mieprex drug label, an abortion by miepristoneconsists o three 200 mg tablets o miepristone taken orally, ollowed by two 200 mcg tablets o misoprostol taken orally, through 49 days LMP (a gestational measurement using the frst day o the woman’s “last menstrual period” as a marker). Te patient is to return or a ollow-up visit in orderto confrm that a complete termination o pregnancy has occurred. Tis FDA-approved protocol isreerred to as the “Mieprex regimen.”3. Te aorementioned treatment requires three oce visits by the patient, and the dosages may only be administered in a clinic, medical oce, or hospital and under supervision o a physician.
4. Te Mieprex fnal printed labeling (FPL) outlines the FDA-approved dosage and administrationo both drugs in the Mieprex regimen, namely miepristone and misoprostol.5. Court testimony by Planned Parenthood and other abortion providers demonstrates that providersroutinely ail to ollow the FDA-approved protocol or the Mieprex regimen, as it is outlined in theMieprex FPL.
Planned Parenthood Cincinnati Region . af
, 459 F. Supp. 2d 626(S.D. Oh. 2006).6. Specifcally, Planned Parenthood and other abortion providers are administering a single oral doseo 200 mg o miepristone, ollowed by a single vaginal or buccal dose o .8 mg misoprostol, through63 days LMP, without medical supervision, and without ollow-up care.
Planned Parenthood Cincinnati Region
, 459 F. Supp. 2d at 630n.7.7. Te use o miepristone presents signifcant medical risks to women, including but not limited toabdominal pain, cramping, vomiting, headache, atigue, uterine hemorrhage, viral inections, pelvicinammatory disease, severe bacterial inection, and death.8. Abortion-inducing drugs are associated with an increased risk o complications relative to surgicalabortion. Te risk o complications increases with advancing gestational age, and, in the instance o miepristone, with ailure to complete the two-step dosage process.
Abortion-Inducing Drugs Safety Act
HOUSE/SENATE BILL NO.